Trial Profile
Clinical Study With Axitinib (AG 013736) In Patients With Metastatic Renal Cell Carcinoma After Failure Of One Prior Systemic First-Line Therapy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 12 Jul 2014
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Pfizer
- 25 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 10 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.